- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Immunoadsorption
Population: Adults (18-64 years)
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Vimida
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- People at high risk of STIs
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- Fragile population
- People at high risk of STIs
- Immunocompromised host
- Men who have sex with men
- People living with HIV
- Hospital
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Vaccination
- VAC∆6
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Hydroxy gas
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition